Comprehensive next-generation sequencing analyses of hypoparathyroidism

Identification of novel GCM2 mutations

Toshikatsu Mitsui, Satoshi Narumi, Mikako Inokuchi, Keisuke Nagasaki, Mie Nakazawa, Goro Sasaki, Tomonobu Hasegawa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Context: In most patients with hypoparathyroidism (HP), the etiology is not defined clinically. Eight genes (AIRE, CASR, CLDN16, GATA3, GCM2, PTH, TBCE, and TRPM6) are known to be responsible genes associated with HP; however, no previous study has screened the eight responsible genes comprehensively in HP patients.

Objectives: This study was conducted to determine the genetic defect in HP patients. We also described clinical and molecular findings of two HP patients with novel GCM2 mutations.

Subjects and Methods: We enrolled 20 nonconsanguineous Japanese patients with child-onset permanentHPwithout22q11deletion. Mutationsandgenomicrearrangementsinvolvingtheeightgenes were screened by targeted next-generation sequencing (NGS). We also screened genetic rearrangements by array comparative genomic hybridization (aCGH) in the mutation-negative patients. A putative deletion, which was suspected by NGS, was additionally analyzed by droplet digital PCR (ddPCR) and junction PCR. Identified novel nucleotide-level GCM2 mutants were characterized in vitro.

Results: We identified seven patients with a single gene disorder, including a CASR mutation, GATA3 mutations, and novel GCM2 mutations (R367Tfs∗15, T370M, and the deletion encompassing exon 1). This submicroscopic deletion, which had been suspected by NGS, could not be detected by aCGH and was confirmed by ddPCR and junction PCR. Functional studies of R367Tfs∗- and T370M-GCM2 demonstrated a reduction of target gene transactivation in both.

Conclusions: Using comprehensive NGS analyses, we identified the genetic defect in 35% of HP patients in our cohort and discovered novel GCM2 mutations including submicroscopic deletion that was undetectable by aCGH.

Original languageEnglish
Pages (from-to)E2421-E2428
JournalJournal of Clinical Endocrinology and Metabolism
Volume99
Issue number11
DOIs
Publication statusPublished - 2014 Nov 1

Fingerprint

Hypoparathyroidism
Genes
Mutation
Comparative Genomic Hybridization
Polymerase Chain Reaction
Defects
Exons
Nucleotides
Transcriptional Activation

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Comprehensive next-generation sequencing analyses of hypoparathyroidism : Identification of novel GCM2 mutations. / Mitsui, Toshikatsu; Narumi, Satoshi; Inokuchi, Mikako; Nagasaki, Keisuke; Nakazawa, Mie; Sasaki, Goro; Hasegawa, Tomonobu.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 99, No. 11, 01.11.2014, p. E2421-E2428.

Research output: Contribution to journalArticle

Mitsui, Toshikatsu ; Narumi, Satoshi ; Inokuchi, Mikako ; Nagasaki, Keisuke ; Nakazawa, Mie ; Sasaki, Goro ; Hasegawa, Tomonobu. / Comprehensive next-generation sequencing analyses of hypoparathyroidism : Identification of novel GCM2 mutations. In: Journal of Clinical Endocrinology and Metabolism. 2014 ; Vol. 99, No. 11. pp. E2421-E2428.
@article{bc2edd5cc4fd4e3d9434db2553e0f88b,
title = "Comprehensive next-generation sequencing analyses of hypoparathyroidism: Identification of novel GCM2 mutations",
abstract = "Context: In most patients with hypoparathyroidism (HP), the etiology is not defined clinically. Eight genes (AIRE, CASR, CLDN16, GATA3, GCM2, PTH, TBCE, and TRPM6) are known to be responsible genes associated with HP; however, no previous study has screened the eight responsible genes comprehensively in HP patients.Objectives: This study was conducted to determine the genetic defect in HP patients. We also described clinical and molecular findings of two HP patients with novel GCM2 mutations.Subjects and Methods: We enrolled 20 nonconsanguineous Japanese patients with child-onset permanentHPwithout22q11deletion. Mutationsandgenomicrearrangementsinvolvingtheeightgenes were screened by targeted next-generation sequencing (NGS). We also screened genetic rearrangements by array comparative genomic hybridization (aCGH) in the mutation-negative patients. A putative deletion, which was suspected by NGS, was additionally analyzed by droplet digital PCR (ddPCR) and junction PCR. Identified novel nucleotide-level GCM2 mutants were characterized in vitro.Results: We identified seven patients with a single gene disorder, including a CASR mutation, GATA3 mutations, and novel GCM2 mutations (R367Tfs∗15, T370M, and the deletion encompassing exon 1). This submicroscopic deletion, which had been suspected by NGS, could not be detected by aCGH and was confirmed by ddPCR and junction PCR. Functional studies of R367Tfs∗- and T370M-GCM2 demonstrated a reduction of target gene transactivation in both.Conclusions: Using comprehensive NGS analyses, we identified the genetic defect in 35{\%} of HP patients in our cohort and discovered novel GCM2 mutations including submicroscopic deletion that was undetectable by aCGH.",
author = "Toshikatsu Mitsui and Satoshi Narumi and Mikako Inokuchi and Keisuke Nagasaki and Mie Nakazawa and Goro Sasaki and Tomonobu Hasegawa",
year = "2014",
month = "11",
day = "1",
doi = "10.1210/jc.2014-2174",
language = "English",
volume = "99",
pages = "E2421--E2428",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Comprehensive next-generation sequencing analyses of hypoparathyroidism

T2 - Identification of novel GCM2 mutations

AU - Mitsui, Toshikatsu

AU - Narumi, Satoshi

AU - Inokuchi, Mikako

AU - Nagasaki, Keisuke

AU - Nakazawa, Mie

AU - Sasaki, Goro

AU - Hasegawa, Tomonobu

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Context: In most patients with hypoparathyroidism (HP), the etiology is not defined clinically. Eight genes (AIRE, CASR, CLDN16, GATA3, GCM2, PTH, TBCE, and TRPM6) are known to be responsible genes associated with HP; however, no previous study has screened the eight responsible genes comprehensively in HP patients.Objectives: This study was conducted to determine the genetic defect in HP patients. We also described clinical and molecular findings of two HP patients with novel GCM2 mutations.Subjects and Methods: We enrolled 20 nonconsanguineous Japanese patients with child-onset permanentHPwithout22q11deletion. Mutationsandgenomicrearrangementsinvolvingtheeightgenes were screened by targeted next-generation sequencing (NGS). We also screened genetic rearrangements by array comparative genomic hybridization (aCGH) in the mutation-negative patients. A putative deletion, which was suspected by NGS, was additionally analyzed by droplet digital PCR (ddPCR) and junction PCR. Identified novel nucleotide-level GCM2 mutants were characterized in vitro.Results: We identified seven patients with a single gene disorder, including a CASR mutation, GATA3 mutations, and novel GCM2 mutations (R367Tfs∗15, T370M, and the deletion encompassing exon 1). This submicroscopic deletion, which had been suspected by NGS, could not be detected by aCGH and was confirmed by ddPCR and junction PCR. Functional studies of R367Tfs∗- and T370M-GCM2 demonstrated a reduction of target gene transactivation in both.Conclusions: Using comprehensive NGS analyses, we identified the genetic defect in 35% of HP patients in our cohort and discovered novel GCM2 mutations including submicroscopic deletion that was undetectable by aCGH.

AB - Context: In most patients with hypoparathyroidism (HP), the etiology is not defined clinically. Eight genes (AIRE, CASR, CLDN16, GATA3, GCM2, PTH, TBCE, and TRPM6) are known to be responsible genes associated with HP; however, no previous study has screened the eight responsible genes comprehensively in HP patients.Objectives: This study was conducted to determine the genetic defect in HP patients. We also described clinical and molecular findings of two HP patients with novel GCM2 mutations.Subjects and Methods: We enrolled 20 nonconsanguineous Japanese patients with child-onset permanentHPwithout22q11deletion. Mutationsandgenomicrearrangementsinvolvingtheeightgenes were screened by targeted next-generation sequencing (NGS). We also screened genetic rearrangements by array comparative genomic hybridization (aCGH) in the mutation-negative patients. A putative deletion, which was suspected by NGS, was additionally analyzed by droplet digital PCR (ddPCR) and junction PCR. Identified novel nucleotide-level GCM2 mutants were characterized in vitro.Results: We identified seven patients with a single gene disorder, including a CASR mutation, GATA3 mutations, and novel GCM2 mutations (R367Tfs∗15, T370M, and the deletion encompassing exon 1). This submicroscopic deletion, which had been suspected by NGS, could not be detected by aCGH and was confirmed by ddPCR and junction PCR. Functional studies of R367Tfs∗- and T370M-GCM2 demonstrated a reduction of target gene transactivation in both.Conclusions: Using comprehensive NGS analyses, we identified the genetic defect in 35% of HP patients in our cohort and discovered novel GCM2 mutations including submicroscopic deletion that was undetectable by aCGH.

UR - http://www.scopus.com/inward/record.url?scp=84909992138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909992138&partnerID=8YFLogxK

U2 - 10.1210/jc.2014-2174

DO - 10.1210/jc.2014-2174

M3 - Article

VL - 99

SP - E2421-E2428

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -